iPSCs hold immense potential in disease modeling and drug screening, and ensuring their pluripotency and viability is crucial to realizing their application value. "Therefore, particular emphasis is placed on iPSC pluripotency characterization services," stated an expert in the field.

Validating and detecting iPSC pluripotency markers significantly benefits subsequent proliferation and differentiation. A series of solutions has been designed to monitor cell pluripotency and genomic stability during large-scale culture.

Quantitative polymerase chain reaction (qPCR) is a cutting-edge technique that can monitor the amplification of target DNA molecules in real-time. Using this technology, the expression levels of pluripotency markers in iPSCs, such as OCT4, SOX2, and NANOG, can be accurately and quantitatively detected.

"Our advanced qPCR analysis for iPSCs includes RNA extraction, cDNA synthesis, primer design and validation, followed by qPCR analysis and comprehensive data analysis."

iPSC pluripotency can also be assessed in vitro. Reprogramming adult somatic cells to an embryonic-like state for iPSC differentiation has already proven feasible. "Therefore, solutions are offered for generating embryoid bodies from iPSCs to achieve in vitro pluripotency assessment."

For large-scale iPSC culture, a focus remains on regulating the complement system, which can influence cell growth and differentiation through various pathways. One critical factor is the anti-factor H autoantibody, which can block the function of factor H. This blockage can lead to overactivation of the complement system, resulting in inflammation and cell damage.

For iPSCs, such overactivation may affect cell survival and the maintenance of pluripotency. Comprehensive anti-factor H autoantibody test services are provided to ensure iPSCs are not adversely affected by complement system dysregulation during culture.